Description
A synthetic peptide agonist of the GIP, GLP-1 and glucagon receptors, studied in metabolic and energy-balance research models.
Formats
Available as a lyophilised-powder vial for reconstitution in the lab, or as a NEXCELL research pen: a sealed, pre-filled format that removes the need for separate reconstitution and keeps research handling organised. Each pen is supplied in a protective NEXCELL presentation box. The pen holds 40 mg of retatrutide in total.
Storage
Store refrigerated between 2 °C and 8 °C. Protect from direct light and excessive heat. Do not freeze. Keep sealed in the original packaging until required for legitimate laboratory research.
Product status
Retatrutide is an investigational compound and is not currently an approved medicine in the United Kingdom. It must not be presented as an approved treatment for any medical condition.
For research purposes only. NEXCELL products are not medicines and are not intended for human consumption, diagnosis, treatment, cure or prevention of disease.


